Kaplan–Meier plots for overall survival (A) in all patients treated with IT therapy; (B) according to BC subtype (HR+/HER2− versus HER2+ versus TN, log-rank P < 0.0001); (C) according to IT agent (methotrexate versus cytarabine or thiotepa, log-rank P = 0.047).
BC, breast cancer; CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IT, intrathecal; OS, overall survival; TN, triple negative.